Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose business model is predicated on animal testing. The company's core pipeline of antibody-based cancer therapeutics requires extensive preclinical testing in animals to advance toward regulatory approval. Its sponsored research agreements with institutions like Memorial Sloan Kettering Cancer Center explicitly anticipate the use of warm-blooded animals in research, mandating compliance with the Animal Welfare Act. This reliance on animal models is fundamental to the company's operations and product development cycle.

The company is listed by Cruelty Free Investors as a firm that conducts animal testing. As a biotechnology entity focused on novel oncology treatments, its research and development activities inherently involve animal experimentation to assess drug efficacy and safety, a standard but exclusionary practice in the pharmaceutical industry.